1. Home
  2. INBX

INBX

Inhibrx Inc.

Logo Inhibrx Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.

Founded: 2010 Country:
United States
United States
Employees: N/A City: LA JOLLA
Market Cap: 1.7B IPO Year: 2020
Target Price: $35.00 AVG Volume (30 days): 726.5K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -5.12 EPS Growth: N/A
52 Week Low/High: $14.31 - $39.79 Next Earning Date: 05-06-2024
Revenue: $1,800,000 Revenue Growth: -17.88%
Revenue Growth (this year): -85.83% Revenue Growth (next year): 698.04%

Share on Social Networks: